Arcturus Therapeutics

Yahoo Finance • 26 days ago

Roth Capital Say Market Pricing Implies Zero Success for Arcturus Therapeutics Holdings Inc. (ARCT) Pipeline Assets

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. The seventeenth stock on our list is Arcturus Therapeutics Holdings Inc. TheFly reported on January 22 that Roth Capital initiated coverage of ARCT with a Buy... Full story

Yahoo Finance • 2 months ago

Cathie Wood tilts toward Robinhood, Bitcoin ETFs, trims Tesla, Iridium

[Bitcoin 2022 Conference Draws Cryptocurrency Industry Professionals And Investors To Miami] Marco Bello Cathie Wood’s ARK Investment Management chopped its holdings in EV maker Tesla (TSLA [https://seekingalpha.com/symbol/TSLA]) and sate... Full story

Yahoo Finance • 3 months ago

Cathie Wood Dumps Tesla Again, Pours Millions Into This Tech Gaint

This article first appeared on GuruFocus. Cathie Wood's ARK Invest funds shifted positions Monday, increasing stakes in Chinese tech giant Baidu (BIDU) while trimming exposure to Tesla (NASDAQ:TSLA). The ARK Innovation ETF (ARKK) purchas... Full story

Yahoo Finance • 4 months ago

Arcturus outlines 12-week cystic fibrosis study launch in 2026 amid cost controls and delayed KOSTAIVE BLA

Earnings Call Insights: Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 MANAGEMENT VIEW * CEO Joseph Payne reported that interim Phase II data for ARCT-032, the company’s mRNA therapeutic candidate for cystic fibrosis (CF), showed "... Full story

Yahoo Finance • 4 months ago

Arcturus cut to Neutral at Citi on data for mRNA candidate

[Business on Wall Street in Manhattan] Pgiam/iStock via Getty Images Arcturus Therapeutics (NASDAQ:ARCT [https://seekingalpha.com/symbol/ARCT]) traded lower on Friday after Citi downgraded the San Diego, California-based biotech, citing m... Full story

Yahoo Finance • 4 months ago

Coinbase, eBay upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Citizens JMP upgraded eBay (EBAY) to O... Full story

Yahoo Finance • 4 months ago

Trending tickers: Tesla, IonQ, IBM, Arcturus and Unilever

Tesla (TSLA) Tesla reported a rebound in quarterly revenue overnight, marking the end of two consecutive periods of decline. However, profits fell sharply as higher costs and lower vehicle prices weighed on the results. The weaker-than-ex... Full story

Yahoo Finance • 5 months ago

Noteworthy Thursday Option Activity: AKRO, DHI, AFRM

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Akero Therapeutics Inc (Symbol: AKRO), where a total of 8,313 contracts have traded so far, representing approximately 831,300 und... Full story

Yahoo Finance • 5 months ago

Cathie Wood's Ark Invest weekly recap: adds Chinese tech names, Intellia Therapeutics

ARK Invest CEO Cathie Wood recently pointed out that the AI space is ruled by “big four” players: OpenAI, Anthropic, Elon Musk’s xAI, and Google’s (GOOG [https://seekingalpha.com/symbol/GOOG]) Gemini, describing the competition among these... Full story

Yahoo Finance • 7 months ago

Meta, Goldman Sachs lead Tuesday's market cap stock movers

Tuesday’s market has seen notable shifts with several stocks making significant intra-day movements. Mega-cap stocks like Facebook Inc (NASDAQ:META) and Goldman Sachs Group (NYSE:GS) are experiencing upward trends, while large-cap stoc... Full story

Yahoo Finance • 7 months ago

Top movers in Tuesday's session

Looking for insights into the US markets in the middle of the day on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT... Full story

Yahoo Finance • 7 months ago

Wells Fargo lowers Arcturus Therapeutics stock price target to $42 on model updates

Investing.com - Wells Fargo lowered its price target on Arcturus Therapeutics (NASDAQ:ARCT) to $42.00 from $45.00 on Tuesday while maintaining an Overweight rating on the stock. The biotech company, currently valued at $309 million, has sh... Full story

Yahoo Finance • 7 months ago

Arcturus outlines pivotal trial plans and advances CF and OTC programs with regulatory meetings expected in 2026

Earnings Call Insights: Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2025 MANAGEMENT VIEW * CEO Joseph E. Payne reported that the ARCT-032 program for Cystic Fibrosis (CF) has completed enrollment and dosing for the 5-milligram cohort... Full story

Yahoo Finance • 7 months ago

Arcturus Therapeutics Holdings Inc earnings missed by $3.55, revenue fell short of estimates

Investing.com - Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) reported second quarter EPS of $-0.34, $3.55 worse than the analyst estimate of $3.21. Revenue for the quarter came in at $28.3M versus the consensus estimate of $191.77M.... Full story

Yahoo Finance • 7 months ago

Arcturus Therapeutics Q2 2025 Earnings Preview

* Arcturus Therapeutics (NASDAQ:ARCT [https://seekingalpha.com/symbol/ARCT]) is scheduled to announce Q2 earnings results on Monday, August 11th, after market close. * The consensus EPS Estimate is -$0.87 [https://seekingalpha.com/symb... Full story

Yahoo Finance • 7 months ago

Barrick Gold, Roivant Sciences, Owens & Minor to report earnings Monday

Earnings season continues, with several notable companies set to release their financial results for the upcoming trading day. Leading the pack are mining giant Barrick Gold, biopharmaceutical company Roivant Sciences (NASDAQ:ROIV), and he... Full story

Yahoo Finance • 8 months ago

Arcturus reports positive phase 2 results for OTC deficiency therapy

SAN DIEGO - Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a $375 million market cap biotech company whose stock has seen a -21% return year-to-date, announced positive interim results from Phase 2 trials of ARCT-810, an mRNA therapeut... Full story

Yahoo Finance • last year

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses CSL Limited (OTC:CSLLY) and Arcturus Therapeutics (NASDAQ:ARCT) announced the results of a Phase 3 head-to-head study of ARCT-154,... Full story

Yahoo Finance • 2 years ago

18 High Growth Low PE Stocks

In this article, we will take a detailed look at the18 High Growth Low PE Stocks. For a quick overview of such stocks, read our article 5 High Growth Low PE Stocks. When value stocks came back with a vengeance in 2022, value investors che... Full story

Yahoo Finance • 2 years ago

12 Best Healthcare Stocks For the Long-Term

In this piece, we will take a look at the 12 best healthcare stocks for the long term. If you want to skip our overview of the healthcare industry, then you can take a look at 5 Best Healthcare Stocks For the Long-Term. The healthcare ind... Full story